Revenue for the first half of FY2026 grew 14.7% year-over-year, driven by strong domestic and overseas sales and higher royalty income. Core net income rose 23.2%, with robust pipeline progress and continued investment in R&D and capital projects.Original document: Chugai Pharmaceutical Co., Ltd…
Revenue for the first half of FY2026 grew 14.7% year-over-year, driven by strong domestic and overseas sales and higher royalty income. Core net income rose 23.2%, with robust pipeline progress and continued investment in R&D and capital projects.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.